The Global Health Body Issues Concern Over Acute Scarcity of Obesity Medications
Under 10% of individuals eligible to benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it releases its inaugural guidance on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Per forecasts, over two billion will be living with obesity by 2030 unless action is taken.
"Our new guidance acknowledges that obesity is a lifelong illness that can be treated with comprehensive and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant obstacles to broad availability to the jabs that can help people shift substantial body mass, says the body.
GLP-1 Therapy Supply Crisis
Despite the current best projected outlook, the manufacturing of GLP-1 therapies might only reach around 100 million people – less than 10% of those who need them, per the health organization.
The advice urges countries and companies to expand availability, via strategies such as voluntary licensing.
The intellectual property rights on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.
How Obesity Injections Work
GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and boost feelings of fullness so users reduce food intake.
Patients commonly start to lose weight within a few weeks of starting on the once-weekly jabs.
Studies indicates patients may put most of the weight back on after a year of halting the medication, because their normal hunger come back.
To be above a healthy weight elevates your risk for developing diseases, like diabetes, heart disease, brain attack, and specific malignancies.
Excess weight impacts individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
